Author

M. A. Şendur

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Real-world outcomes of second-line therapy in advanced thymic carcinoma: a multicenter Turkish Oncology Group (TOG) study

Thymic carcinoma (TC) is a rare and aggressive malignancy with limited evidence guiding second-line treatment after prior systemic therapy. We evaluated real-world outcomes of second-line systemic therapy in a multicenter cohort. Adults with unresectable, recurrent, or metastatic TC who received second-lin...

Fatih Kuş, Fatih Atalah, Gökhan Şahin et al. · BMC Cancer · 0 citations

Open access Sep 2026

Association Between ABO Blood Group and Survival Outcomes in Advanced NSCLC Treated with Immune Checkpoint Inhibitors

Background: Reliable biomarkers that predict outcomes with immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC) remain limited. ABO blood group antigens may influence tumor immunity and response to immunotherapy. Methods: We retrospectively analyzed 239 patients with advanced NSCLC treated with ICI...

H. Karakaş, S. C. Efil, B. Bilgin et al. · Current Oncology · 0 citations